Finerenone reduces risk of cardiovascular and kidney outcomes associated with T2D

According to the recent clinical study report, finerenone provides better control of cardiovascular (CV) and kidney outcomes in patients with T2D and chronic kidney disease. This study was published in the European Heart Journal. Cardiovascular Pharmacotherapy.

This randomized controlled study aimed to compare finerenone vs. placebo in patients with and without baseline history of atherosclerotic CV disease (ASCVD). The outcomes evaluated were composite CV outcome, CV death or HHF, and a composite kidney outcome, all-cause mortality, and safety.

45.6% of the patients included in the study had a history of ASCVD. The occurrence of composite CV outcome, CV death or HHF, and all-cause mortality was higher in patients with ASCVD vs. those without. Finerenone reduced outcomes in patients with and without ASCVD, compared to placebo.

Based on the results of the study, finerenone can decrease the risk of CV and kidney outcomes consistently across the spectrum of CKD in patients with T2D, irrespective of prevalent ASCVD.